Maternal Buprenorphine Treatment and Fetal Neurobehavioral Development. Issue 1 (March 2018)

• Record Type: Journal Article
• Authors: Jansson, L.M.; Velez, M.; McConnell, K.; Spencer, N.; Tuten, M.; Jones, H.E.; King, V.L.; Gandotra, N.; Milio, L.A.; Voegtline, K.; DiPietro, J.A.
• Is Part Of: Obstetric anesthesia digest. Volume 38:Issue 1(2018)
• Publication Date: 2018-03
• Subjects: Drug Abuse in Pregnancy -- Pharmacology -- Non-obstetric Maternal Disease -- Neonatal Morbidity and Mortality; Anesthesia in obstetrics -- Periodicals; Anesthesia in obstetrics -- Abstracts -- Periodicals; 617.968205
• DOI: 10.1097/01.aoa.0000530008.76097.57
• Languages: English
• ISSNs: 0275-665X

Abstract

Abstract : ( Am J Obstet Gynecol . 2017;216(5):529.e1–529.e8) Opioid usage is increasing among pregnant mothers in the United States, which can lead to neonatal abstinence syndrome in their children. Previous studies have shown less severe neonatal abstinence syndrome in infants whose mothers were treated for opioid use with buprenorphine rather than methadone. This study looked at the effects of buprenorphine on fetal activity and development.